Threshold Pharmaceuticals (THLD) Global Agreement with Merck KGaA

CRWENewswire, Stocks to Watch. Threshold Pharmaceuticals Inc - THLD - reported that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold’s small molecule hy...

CRWENewswire, Stocks to Watch. Threshold Pharmaceuticals Inc - THLD
- reported that a global agreement was signed with Merck KGaA,
Darmstadt, Germany, to co-develop and commercialize TH-302,
Threshold’s small molecule hypoxia-targeted drug. Threshold will
receive an upfront payment of $25 million and could receive up to
$35 million in additional development milestones during 2012.
Threshold is also eligible to receive a $20 million milestone
payment based on positive results from its randomized Phase 2 trial
in pancreatic cancer. Total potential milestone payments are $525
million, comprised of $280 million in regulatory and development
milestones and $245 million in sales-based
milestones.

***********************

THIS IS NOT A
RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at
http//crwenewswire.com/disclaimer).